PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 1002-1002 ◽  
Author(s):  
Jonas C. S. Bergh ◽  
Theodoros Foukakis ◽  
Gunter von Minckwitz ◽  
Nils-Olof Bengtsson ◽  
Birgitta Wallberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Dose Dense ◽  
Modern Era ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Dose-Dense Sequential Adjuvant Chemotherapy with Epirubicin, Paclitaxel and CMF in High-Risk Breast Cancer

Oncology ◽  
2001 ◽  
Vol 60 (3) ◽  
pp. 214-220 ◽  
Author(s):  
G. Fountzilas ◽  
C. Papadimitriou ◽  
G. Aravantinos ◽  
C. Nicolaides ◽  
G. Stathopoulos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Dose Dense ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Filgrastim and Lack of Support of Intensive Adjuvant Chemotherapy for High-Risk Breast Cancer Patients

1997 ◽  
Vol 20 (2) ◽  
pp. 169-172 ◽  
Author(s):  
Editta Baldini ◽  
Carmelo Tibaldi ◽  
Monica Lencioni ◽  
Piergiorgio Giannessi ◽  
Giuseppe Evangelista ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document